

July 14, 2025



Kane Biotech to Present at Advanced Wound Care Summit USA

WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) ("Kane Biotech" or "Kane") announces today that Kane Biotech's Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the 4th Advanced Wound Care Summit USA taking place from July 15-17, 2025 in Boston, MA.

The Advanced Wound Care Summit USA is an industry gathering dedicated to the business of wound care where innovators, payers, regulators, and multinational leaders come together to turn breakthrough science into profitable, accessible therapies.

Dr. Huizinga's presentation will be available on Kane's website as of July 16, 2025.

About Kane Biotech

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve™ addresses both biofilms and wound bacteria.

For more information:

Dr. Robert Huizinga
Interim CEO
Kane Biotech Inc
rhuizinga@kanebiotech.com
(780) 970-1100

Ray Dupuis
Chief Financial Officer
Kane Biotech Inc
rdupuis@kanebiotech.com
(204) 298-2200

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Information

This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development,

government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar+.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.



Source: Kane Biotech Inc.